The applying from Lykos — a drug company incubated via the Multidisciplinary Association for Psychedelic Scientific tests, or MAPS — arrived within the FDA less than a cloud of controversy. Former demo contributors experienced alleged adverse situations weren't claimed — which includes emotions of suicidality after the cure — Which bias amo